Kailera Therapeutics KLRA
Drug Manufacturers - General, Healthcare
$12.85
−3.17%
- Market cap
- $1.7B
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| R&D | $10.1M | $19.5M | $70.9M | $101.1M |
| SG&A | $10.3M | $11.1M | $13.8M | $20.3M |
| −$20.5M | −$30.7M | −$84.7M | −$121.4M | |
| Net income | −$18M | −$28.9M | −$78.9M | −$111.3M |
| −$17983.00 | −$28947.00 | −$3650.00 | −$1.09 | |
| 1K | 1K | 21.6K | 102.2M |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Kailera Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KLRAKailera Therapeutics | $1.7B | n/m | n/a | n/m | n/m | n/m | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| Peer median | $1.5B | 12.5× | 17.9× | 2.0× | +11% | 13.3% |
More on Kailera Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .